@FAndreMD's research group at the @GustaveRoussy in France recently published an article in #Nature about 1462 patients with non-HER2-overexpressing metastatic #breastcancer who underwent genomic analysis in the SAFIR02-BREAST trial. https://t.co/1tOaewgMP
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
RT @VivekSubbiah: Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https…
Genomics to select treatment for patients with metastatic breast cancer @FAndreMD @Nature @Annals_Oncology @myESMO https://t.co/VzwFkP0zau
RT @kazuki_nozawa: Natureに載ったのですね…転移再発乳がんに対して、ESCATレベルで分類されたprecision medicineの有効性を検討したSAFIR02-BREAST試験。当然ながらActionable遺伝子異常があれば、PFSを延長させる。…
あとでよむ Genomics to select treatment for patients with metastatic breast cancer https://t.co/bWoSGvbJd5
RT @alitimumab: Overview of #PrecisionOncology in #BreastCancer by @FAndreMD at #WINSympo2022 Some ref 👇🏼 https://t.co/Ugceqh9egM https:/…
RT @alitimumab: Overview of #PrecisionOncology in #BreastCancer by @FAndreMD at #WINSympo2022 Some ref 👇🏼 https://t.co/Ugceqh9egM https:/…
RT @Aviavipshaapal: Something very insightful and making therapy more individualized... unmet need for every cancer type..
Something very insightful and making therapy more individualized... unmet need for every cancer type..
RT @alitimumab: Overview of #PrecisionOncology in #BreastCancer by @FAndreMD at #WINSympo2022 Some ref 👇🏼 https://t.co/Ugceqh9egM https:/…
RT @alitimumab: Overview of #PrecisionOncology in #BreastCancer by @FAndreMD at #WINSympo2022 Some ref 👇🏼 https://t.co/Ugceqh9egM https:/…
Ali, let’s create a start-up on this topic of « personalized drug », ie construct a drug specifically for a single patient, like haute couture.
Overview of #PrecisionOncology in #BreastCancer by @FAndreMD at #WINSympo2022 Some ref 👇🏼 https://t.co/Ugceqh9egM https://t.co/xiZ2wWZ9uv #CANcerTOxicities cohort study (CANTO) is open for research ideas https://t.co/739sbEPkfD Future direction 👇🏼 htt
進行転移乳癌1400例以上について、ゲノム解析+アレイCGHを利用してランダム化比較試験の割り振りを決めたところ、ESCATエビデンスレベルII以上でなければ無増悪生存期間が伸びないという、これNatureですか?という感じの論文。 https://t.co/O60ewh8Env
Nature ハイライト:ゲノム変化に基づく乳がん治療法の選択 | Nature | Nature Portfolio https://t.co/MVvsTnxBoC
SAFIR-02 Breast https://t.co/Y0mLa0SOPF
RT @GPharmatech: Researchers at the Université Paris-Saclay @UnivParisSaclay tested targeted therapies based on genomic analysis and recent…
RT @GPharmatech: Researchers at the Université Paris-Saclay @UnivParisSaclay tested targeted therapies based on genomic analysis and recent…
Researchers at the Université Paris-Saclay @UnivParisSaclay tested targeted therapies based on genomic analysis and recently published the results in #Nature. https://t.co/iEe2K2Uw7g #genomics #genome #dnasequencing #oncogene #cancer #cancerresearch
RT @BioDecoded: Genomics to select treatment for patients with metastatic breast cancer | Nature https://t.co/dCsn41BtLS #CancerResearch
RT @BioDecoded: Genomics to select treatment for patients with metastatic breast cancer | Nature https://t.co/dCsn41BtLS #CancerResearch
RT @BioDecoded: Genomics to select treatment for patients with metastatic breast cancer | Nature https://t.co/dCsn41BtLS #CancerResearch
RT @BioDecoded: Genomics to select treatment for patients with metastatic breast cancer | Nature https://t.co/dCsn41BtLS #CancerResearch
Genomics to select treatment for patients with metastatic breast cancer | Nature https://t.co/dCsn41BtLS #CancerResearch
RT @SidYadavMD: The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for m…
RT @SidYadavMD: The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for m…
RT @SidYadavMD: The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for m…
がん:乳がんの個別化治療の転帰がゲノミクスによって決まるかもしれない | Nature | Nature Portfolio https://t.co/Os9akkBJTV
RT @SidYadavMD: The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for m…
RT @Nature: Nature research paper: Genomics to select treatment for patients with metastatic breast cancer https://t.co/8UDrNis06n
RT @SidYadavMD: The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for m…
RT @SidYadavMD: The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for m…
The results of SAFIR 02 Breast study, while exciting, is also sobering as less than 10% of those undergoing tumor NGS for metastatic breast ca were found to have actionable mutations in genes other than PIK3CA. https://t.co/ce2dGNRCoI https://t.co/y4BLgPT
RT @LMU_RadOnc: Important data - future of cancer therapies https://t.co/CqxnM5WzSg
Important data - future of cancer therapies https://t.co/CqxnM5WzSg
RT @Nature: Nature research paper: Genomics to select treatment for patients with metastatic breast cancer https://t.co/8UDrNis06n
Our technological abilities have outpaced our biological knowledge. Only patients with ESCAT level I/II genomic alterations (<50% of patients) benefit from precision medicine options. Patients with ESCAT level II+ genomic alterations do not. https://t.c
RT @NatureJapan: がん:乳がんの個別化治療の転帰がゲノミクスによって決まるかもしれない 注目のハイライト | Nature #がん #乳がん #ゲノミクス https://t.co/SbcXgGdizY
RT @mtmdphd: Genomics to select treatment for patients with metastatic breast cancer [Sep 7, 2022] @FAndreMD et al. @Nature https://t.co/G…
RT @Nature: Nature research paper: Genomics to select treatment for patients with metastatic breast cancer https://t.co/8UDrNis06n
RT @mtmdphd: Genomics to select treatment for patients with metastatic breast cancer [Sep 7, 2022] @FAndreMD et al. @Nature https://t.co/G…
Genomics to select treatment for patients with metastatic breast cancer [Sep 7, 2022] @FAndreMD et al. @Nature https://t.co/GmstPDY6yY #PrecisionMedicine #bcsm #camets SAFIR02-BREAST trial n=1462 Pts w/ non-HER2 mBrCA -> 238 on RCTs. HT @DrChoueiri
がん:乳がんの個別化治療の転帰がゲノミクスによって決まるかもしれない | Nature | Nature Portfolio: https://t.co/UpNB3ve9IR
RT @deepgreendesign: Genomics to select treatment for patients with metastatic breast cancer c/o @Nature ~ https://t.co/SJk7arrScr #Geneti…
RT @Nature: Nature research paper: Genomics to select treatment for patients with metastatic breast cancer https://t.co/8UDrNis06n
RT @Nature: Nature research paper: Genomics to select treatment for patients with metastatic breast cancer https://t.co/8UDrNis06n
Nature research paper: Genomics to select treatment for patients with metastatic breast cancer https://t.co/8UDrNis06n
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
@Nature paper on genomic alterations in today's #APaperADay challenge. The authors show that targeted therapies matched to genomics improves progression-free survival (PFS) when genomic alterations are classified as level I/II according to the ESMO scale.
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
Genomics to select treatment for patients with metastatic breast cancer - https://t.co/s2R08YVF7W https://t.co/wM6em9ItBY
RT @euanashley: 1. @nature publishes clinical trials now 2. "This trial provides evidence that the treatment decision led by genomics shou…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FilippoMontemu1: Genomics to select treatment for patients with metastatic breast cancer https://t.co/VI8IJJLn3E In a world where techn…
$F.C - BR: $25.99 -> NOW: $23.88 Genomics to select treatment for patients with metastatic breast cancer Read more: https://t.co/HnWp8lTs1D
CLINICAL BRIEFINGS: #Precisionmedicine improves outcomes in metastatic #breastcancer @Nature https://t.co/WmjoC4c3LK #PM101 #ESCAT #cancer #clinicaltrials #Genomics to select treatment for patients w/ #metastaticbreastcancer https://t.co/R4aNWiLYO9 NB: h
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
RT @senologieSFSPM: Bénéfice des traitements ciblés en fonction de l’anomalie moléculaire dans le cancer du sein métastatique. Résultats ex…
RT @FilippoMontemu1: Genomics to select treatment for patients with metastatic breast cancer https://t.co/VI8IJJLn3E In a world where techn…
Genomics to select treatment for patients with metastatic breast cancer https://t.co/VI8IJJLn3E In a world where technology runs way faster than our ability to govern it, this paper teaches a lot of lessons. Congrats to @FAndreMD ad co-investigators and th
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @NCIEytanRuppin: Genomics to select treatment for patients with metastatic breast cancer @Nature https://t.co/RKsDoUwOcT https://t.co/V…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @euanashley: 1. @nature publishes clinical trials now 2. "This trial provides evidence that the treatment decision led by genomics shou…
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
Genomics to select treatment for patients with metastatic breast cancer https://t.co/0M6uNFjkPm
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
Precision medicine coming to life https://t.co/Uq7ZXOsqLb
RT @euanashley: 1. @nature publishes clinical trials now 2. "This trial provides evidence that the treatment decision led by genomics shou…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @euanashley: 1. @nature publishes clinical trials now 2. "This trial provides evidence that the treatment decision led by genomics shou…
RT @euanashley: 1. @nature publishes clinical trials now 2. "This trial provides evidence that the treatment decision led by genomics shou…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
RT @PTarantinoMD: Landmark publication of SAFIR02-BREAST on @Nature, demonstrating the importance of classifying genomic alterations by lev…
RT @FAndreMD: SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No dete…